Onexton Availability in 2026: A Provider Briefing

If your patients are reporting difficulty filling Onexton prescriptions, you're not alone in hearing it. While Onexton (Clindamycin Phosphate 1.2% / Benzoyl Peroxide 3.75%) is not on the FDA's formal drug shortage list, practical availability challenges are creating real barriers to patient access. This briefing covers the current landscape, prescribing implications, and tools to help your patients get the treatment they need.

Timeline: How We Got Here

Onexton was FDA-approved in November 2014 as a once-daily topical acne treatment manufactured by Bausch Health (formerly Valeant Pharmaceuticals). It differentiated itself from older clindamycin/benzoyl peroxide combinations by using a lower benzoyl peroxide concentration (3.75% vs. 5%) while maintaining the standard clindamycin phosphate dose (1.2%).

Key milestones:

• November 2014: FDA approval of Onexton
• January 2018: Perrigo receives tentative FDA approval for a generic version
• 2018–2026: No generic has been launched despite tentative approval
• 2024–2026: Increasing patient reports of pharmacy non-stocking and access difficulties

The absence of generic competition after more than a decade on the market is the primary driver of the current access problem.

Prescribing Implications

Formulary Positioning

Onexton is consistently placed on Tier 3 (non-preferred brand) or higher across most commercial formularies. Key coverage patterns include:

• Prior authorization is required by most major payers
• Step therapy is standard — patients typically must fail generic clindamycin/benzoyl peroxide (1.2%/2.5% or 1%/5%) before Onexton is approved
• Some plans exclude Onexton entirely, particularly Medicaid managed care plans
• Medicare Part D plans rarely cover topical acne medications for beneficiaries over 65

Clinical Considerations

When deciding whether to prescribe Onexton vs. alternatives, consider:

• The 3.75% benzoyl peroxide concentration may be better tolerated in patients with sensitive or dry skin compared to 5% formulations
• Once-daily application improves adherence, which is critical for acne outcomes
• The combination reduces antibiotic resistance risk compared to topical clindamycin monotherapy
• Refrigeration requirement may impact patient compliance — ensure patients understand storage instructions

Current Availability Picture

Onexton is manufactured and distributed by Bausch Health through standard pharmaceutical wholesale channels. There is no manufacturing disruption or formal shortage.

However, availability at the pharmacy level is limited because:

• High unit cost: Wholesale acquisition cost is high, and retail prices range from $400 to $990 per 50g pump
• Refrigeration burden: Requires cold storage (36°F–46°F) with a 10-week expiration after dispensing
• Low fill volume: Insurance barriers and cost reduce prescription volume, making stocking uneconomical for many pharmacies
• No generic: Pharmacy substitution is not possible, as no AB-rated generic exists

Cost and Access Landscape

Understanding the financial landscape helps when counseling patients:

Patient Cost Summary

• Retail cash price: $400–$990 per 50g pump
• Discount card pricing: SingleCare approximately $93; GoodRx approximately $700–$870
• Bausch + Lomb Access Program: Copay as low as $25 for commercially insured patients (not valid for government insurance)
• Bausch Health Patient Assistance Program: Free medication for eligible uninsured/underinsured patients meeting income requirements (bauschhealthpap.com)

Generic Alternative Pricing

• Generic Clindamycin/Benzoyl Peroxide 1.2%/2.5% (Acanya generic): $30–$80
• Generic Clindamycin/Benzoyl Peroxide 1%/5% (BenzaClin generic): $25–$70
• Generic Clindamycin/Benzoyl Peroxide 1.2%/5% (Duac generic): $30–$90

Tools and Resources for Your Practice

Several tools can help streamline the process of getting patients access to acne treatment:

Medfinder for Providers

Medfinder allows providers to check real-time pharmacy inventory for Onexton and direct patients to pharmacies with current stock. This can be integrated into your workflow to reduce callback volume from patients struggling to fill prescriptions.

Prior Authorization Support

When filing PAs for Onexton, document:

• Previous trials and failures of generic clindamycin/benzoyl peroxide combinations
• Clinical rationale for the lower 3.75% benzoyl peroxide concentration (e.g., skin sensitivity, irritation with higher concentrations)
• Patient adherence history with once-daily vs. twice-daily regimens

Patient Savings Resources

Direct patients to:

• Bausch + Lomb Access Program: bauschaccessprogram.com or 1-877-494-4372
• Bausch Health Patient Assistance Program: bauschhealthpap.com
• Prescription discount cards: SingleCare, GoodRx, RxSaver

For a comprehensive patient-facing guide, you can share: How to Save Money on Onexton

Looking Ahead

The Onexton availability situation is unlikely to change significantly in the near term without generic market entry. Key factors to monitor:

• Whether Perrigo or another manufacturer launches a generic Clindamycin 1.2% / Benzoyl Peroxide 3.75% product
• Formulary changes during the 2026 plan year that may affect coverage
• New combination acne products entering the market (e.g., Cabtreo, which adds adapalene to clindamycin/benzoyl peroxide)

In the meantime, having a clear step-therapy pathway — starting with generic alternatives and escalating to Onexton with proper PA documentation — gives patients the best chance of accessing appropriate treatment.

Final Thoughts

Onexton remains a valuable tool in the acne treatment arsenal, particularly for patients who benefit from its lower benzoyl peroxide concentration and once-daily convenience. The access challenges are real but manageable with the right workflow: use Medfinder for Providers to check availability, prepare strong PA documentation, direct patients to savings programs, and have generic alternatives ready as a backup plan.

For a practical guide to helping patients locate Onexton, see our companion article: How to Help Your Patients Find Onexton in Stock.